| Bioactivity | Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect[1]. |
| CAS | 2675496-01-0 |
| Sequence | Tyr-{Aib}-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Tyr-Leu-Glu-Lys-Ile-Ala-Ala-Gln-Glu-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-{Lys((AEEA)2-γGlu-C20 diacid)}-NH2 |
| Shortening | Y-{Aib}-EGTFTSDYSIYLEKIAAQEFVNWLLAGGPSSGAPPPS-{Lys((AEEA)2-γGlu-C20 diacid)}-NH2 |
| Formula | C235H357N49O72 |
| Molar Mass | 5020.63 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Olatorepatidum (Olatorepatide). WHO Drug Information, Vol. 37, No. 4, 2023. |
Olatorepatide
CAS: 2675496-01-0 F: C235H357N49O72 W: 5020.63
Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.